Relevance. The sulfation of homocysteine is an important element in protecting cells against ischemic-reperfusion injury. In clinical studies the positive effect of N-acetylcysteine on the reduction of necrosis was found in patients with STEMI.
Objective of this study was to evaluate the baseline levels of sulphur-containing amino acids in plasma as predictors of early (on the day of admission) systolic dysfunction of left ventricle (SDLV) and acute heart failure (HF) in patients with STEMI without reperfusion therapy (RT).
Material and methods. 92 patients with STEMI without RT were examined. The content of free plasma sulphur-containing aminо acids (homocysteine, cysteine and methionine) was investigated on the day of admission by ion-exchanged liquid-column chromatography.
Results. The complications of STEMI were associated with increased baseline levels of sulphur-containing aminо acids, especially, cysteine and methionine. Its levels were significantly higher (at 71.7%, р<0.01, and 41.3%, р<0.05, respectively) in patients with early SDLV compared with patients with ejection fraction of left ventricle (LVEF) >40%. The multivariate logistic regression analysis revealed that the baseline level of cysteine in patients with STEMI remained an independent predictor of early (on the day of admission) SDLV (OR=17.4, p<0.001) after adjustment for anamnestic and laboratory factors. The sensitivity and specificity of baseline cysteine level >0.49 mg/dl as a marker of early SDLV were 73.9% and 65.2% respectively (AUC=0.72, p=0.006). The multivariate analysis revealed that the baseline level of methionine was an independent predictor of acute HF on the day of admission after adjustment for laboratory factors (OR=25.9, p<0.001). Also methionine was an independent predictor of persistent / late HF on third day or later in total sampling (OR=25.9, p<0.001) after adjustment for demographic, anamnestic and clinic factors (OR=68.7, p<0.0001), as well as after adjustment for laboratory risk factors (OR=42.5, p<0.0001). The sensitivity and specificity of baseline methionine level >0.31 mg/dl as a marker of persistent / late HF were 87.5% and 63.3% respectively (AUC = 0.77, p <0.0001). Also the baseline level of methionine was an independent predictor of persistent / late HF in patients with EFLV >40% after adjustment for demographic and anamnestic factors (OR=113.3, p <0,0001). The sensitivity and specificity of methionine level >0.41 mg/dl as a marker of persistent / late HF in patients with EFLV >40% were 80.0% and 81.0% respectively (AUC=0.80, р<0.0001).
Conclusions. The complicated course of STEMI without RT is associated with increased level of sulphur-containing aminо acids, especially, cysteine and methionine. A higher level of cysteine is associated with early SDLV independently from anamnesis risk factors and creatinine level in plasma. The risk of persistent / late HF (on third day and later) is associated with a higher level of methionine independently from demographic, anamnestic, clinical and laboratory factors risk.
Kozarenko T.D. Amino Acid Chromatography of Amino Acids. Novosibirsk: Nauka, 1975. 134 p.
Stress and diseases of the circulatory system: tutorial / Edited by V.M. Kovalenko and V.M. Kornatsky. Kyiv. 2015. 354 p.
Feyhenbaum H. Echocardiography. / Edited by V.V. Mitkov. 5 edition. Moskow: Vidar. 1999. 512 p.
Admission homocysteine is an independent predictor of spontaneous reperfusion and early infarct-related artery patency before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction / Li J. et al. // BMC Cardiovascular Disorders. 2018. V.18. No. 1. P.125. URL : https://doi.org/10.1186/s12872-018-0868-3
Assessment of plasma aminothiol levels and the association with recurrent atherothrombotic events in patients hospitalized for an acute coronary syndrome: a prospective study / Focks J.J. et al. // Clin. Chem. Lab. Med. 2013. V. 51, No. 11. P. 2187-2193. doi: 10.1515 / cclm-2013-0103.
Bearden S.E., Beard R.S.Jr., Pfau J.C. Extracellular transsulfuration generates hydrogen sulfide from homocysteine and protects endothelium from redox stress // Am. J. Physiol. Heart Circ. Physiol. 2010. V. 299. No. 5. P. H 1568-H 1576. doi: 10.1152 / ajpheart.00555.2010.
Cohen M.V., Downey J.M. Cardioprotection: spotlight on PKG // Br. J. Pharmacol. 2007. V. 152. No. 6. P. 833-834. DOI: 10,1038 / sj.bjp.0707453
Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men / Mansoor M.A. et al. // Clin. Chem. 1992. V. 38. No. 7. P. 1316-1321.
Early use of N-acetylcysteine (NAC) with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction reduces myocardial infarct size (The NACIAM Trial) / Pasupathy S. et al. // Circulation. 2017. V. 136. No. 10. P. 894-903. URL: https://doi.org/10.1161/circulationaha.117.027575
Garlick P.J. Toxicity of methionine in humans // J. Nutr. 2006. V. 136. P. 1722S-1725S. doi: 10.1093 / jn / 136.6.1722S.
Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 / Xie W. et al. // Diabetes. 2013. V. 62. No. 6. P. 2141-2150. doi: 10.2337 / db12-0876.
Go Y.-M., Jones D.P. Cysteine/cystine redox signaling in cardiovascular disease // Free Radic. Biol. Med. 2011. Vol. 50. No. 4. P. 495-509. doi: 10.1016 / j.freeradbiomed.2010.11.029.
Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection // Heart Fail. Rev. 2007. V. 12. No. 3-4. P. 217-234. DOI: 10,1007 / s10741-007-9026-1
Heart disease and stroke statistics-2014 update: a report from the American Heart Association / Go A.S. et al. // Circulation. 2014. V.129. No 3. P. e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.
Homocysteine and heart failure: an overview / Vizzardi E. et al. // Recent Patents on Cardiovascular Drug Discovery. 2009. V. 4. No. 1. P. 15-21. PMID: 19149701
Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? // J. Mol. Cell. Cardiol. 2009. V. 47. No. 1. P. 32-40. doi: 10.1016 / j.yjmcc.2009.03.019.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation / Van de Werf F. et al. // Eur. Heart J. 2008. V. 29. No. 23. P. 2909-2945. doi: 10.1093 / eurheartj / ehn416.
Protection from reperfusion injury with intracoronary N-acetylcysteine in patients with STEMI undergoing primary percutaneous coronary intervention in a cardiac tertiary center / Nozari Y. et al. // Am J Cardiovasc Drugs. 2018. V.18. No. 3. P. 213-221. URL: https://doi.org/10.1007/s40256-017-0258-8
Obeid O. A. Plasma amino acid concentrations in patients with coronary heart disease: a comparison between UK Indian Asian and Caucasian men // Int. J. Vitam. Nutr. Res. 2005. V. 75. No. 4. P. 267-273. DOI: 10,1024 / 0300-98188.8.131.527
Piper H.M. Garcia-Dorado D. Reducing the impact of myocardial ischaemia/reperfusion injury // Cardiovascular Research. 2012. V. 94. No. 2. P. 165-167. doi: 10.1093 / cvr / cvs133.
Pisarenko O.I. Mechanisms of myocardial protection by amino acids: facts and hypotheses // Clinical and Experimental Pharmacology and Physiology. 1996. V. 23. No. 8. P. 627-633. URL: http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1681.1996.tb01748.x/abstract
Screening of toxicity biomarkers for methionine excess in rats / Toue S. et al. // J. Nutr. 2006. V. 136. P. 1716S-1721S. doi: 10.1093 / jn / 136.6.1716S.
The coronary circulation in cardioprotection: more than just one confounder / Heusch G. et al. // Cardiovascular Research. 2012. V. 94. No. 2. P. 237-245. doi: 10.1093 / cvr / cvr271.
Thiol redox homeostasis in neurodegenerative disease / McBean G.J. et al. // Redox Biology. 2015. No. 5. Р. 186-194. doi: 10.1016/j.redox.2015.04.004.
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology / Hausenloy D.J. et al. // Cardiovascular Research. 2013. V. 98. P. 7-27. doi: 10.1093 / cvr / cvt004.
This work is licensed under a Creative Commons Attribution 4.0 International License.